Industry calls for revisions of FDA’s REMS draft guidance
Regulatory NewsJoanne S. Eglovitch
Advertising, Promotion and LabelingCDERComplianceGuidancePharmaceuticalsProduct developmentRisk managementSafety communicationUnited StatesRegulatory NewsJoanne S. EglovitchAdvertising, Promotion and LabelingCDERComplianceGuidancePharmaceuticalsProduct developmentRisk managementSafety communicationUnited States